Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ebola survivors get vaccine booster to ward off return of the virus

NCT ID NCT05992480

Vaccine Sponsor: Tulane University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a booster dose of the Ebola vaccine (ERVEBO) can strengthen the immune system of people who have already survived Ebola. Researchers will compare their response to that of healthy people who have never had the virus. The goal is to see if the booster provides lasting protection and is safe for survivors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ebola virus vaccine (ERVEBO)
What this could lead to
If successful, this could show that a booster shot helps Ebola survivors maintain long-term protection against reinfection.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply broadly. The vaccine may cause side effects like fever or muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * EVD survivors * History of admission and discharge from an Ebola Treatment Unit as registered by the Sierra Leone Association of Ebola Survivors (SLAES). * Anti-EBOV GP IgG positive by ELISA at the time of screening. * ≥18 years of age. * \>45.5 kg (100lbs). * Willingness to provide informed, written consent. * Willingness to undergo all study procedures including rVSVDG-ZEBOV-GP vaccination and multiple blood collections over a period of six months. * Age- and sex-matched controls * Anti-EBOV GP IgG negative by ELISA at the time of screening. * ≥18 years of age. * Willingness to provide informed consent. * Willingness to undergo all study procedures including rVSVDG-ZEBOV-GP vaccination and multiple blood collections over a period of six months. Exclusion Criteria: * Have received the rVSVDG-ZEBOV-GP vaccine. * Currently participating in another clinical trial involving a vaccine. * Received a live vaccine within four weeks of screening. * \<18 years of age. * Weight \<45.5kg (or 100 lbs). * Refusal to provide informed, written consent. * Prisoners of other institutionalized individuals. * Research study staff and their immediate family members. * Inability to participate in research activities. * Pregnant and lactating females. * Known immunocompromised status. * Known allergy to vaccine components.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ebola virus disease

Contacts and locations

Locations

  • Kenema Government Hospital

    Kenema, Eastern Province, Sierra Leone

More trials for these conditions

Other studies related to the condition(s) this trial covers.